<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676830</url>
  </required_header>
  <id_info>
    <org_study_id>K-312-1.03US</org_study_id>
    <nct_id>NCT02676830</nct_id>
  </id_info>
  <brief_title>Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Institute, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluation of absorption, metabolism, and excretion of
      [14C]-K-312 and estimation of the absolute bioavailability of K-312 in healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma-concentration time curve to last measured time point</measure>
    <time_frame>336 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral bioavailability based on the ratio of AUC after oral dosing to the AUC after i.v. dosing</measure>
    <time_frame>336 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>K-312</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-312 100 mg</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>K-312</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-312 100 ug C14 IV</intervention_name>
    <description>microtracer dose containing â‰¤37 kBq (1000 nCi) [14C] given as a 5-ml IV push over 2 minutes</description>
    <arm_group_label>K-312</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject provides written informed consent before any study-specific evaluation is
             performed.

          -  Subject is a healthy adult male between the ages of 25 and 45 years, inclusive.

          -  Subject has a body mass index (BMI) of 18.5 to 30 kg/m2, inclusive.

        Exclusion Criteria:

          -  Presence of active or recurring clinically significant cardiovascular, pulmonary,
             renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic,
             gastrointestinal, or metabolic disease requiring medical treatment.

          -  Any surgical or medical condition that might significantly alter the absorption,
             distribution, metabolism, or excretion of K-312.

          -  Clinically relevant abnormalities in clinical laboratory parameters, as judged by the
             Investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

